Science AI Journal
Medicine · Research topic

Open research questions in Chronic Lymphocytic Leukemia Research

315 gap statements mined from Chronic Lymphocytic Leukemia Research papers in our 7.9M-paper local library, which holds 1,599 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Chronic Lymphocytic Leukemia Research? See the ranked Medicine journals.

What the literature leaves open

  • The lack of understanding of the immune mechanisms underlying the onset of AIHA. The need for dedicated clinical trials to compare the efficacy of different targeted therapies.

    Autoimmune hemolytic anemia and chronic lymphocytic leukemia: crossing the borders between autoimmunity and malignancy · 2026 · DOI

  • The prognostic value of residual monotypic plasma cells after chemoimmunotherapy in patients with Waldenström macroglobulinemia remains unclear. There is a need to investigate the clinical and biological differences in patients with a plasma cell infiltrate ≥10% in baseline bone marrow biopsy.

    Prognostic significance of monotypic plasma cell infiltration of the bone marrow in patients with Waldenström macroglobulinemia · 2026 · DOI

  • The immune evasion phenotype of HRS cells in CHL-RT is not well understood. The genetic features of precursor CLL/SLL in CHL-RT are not well defined. The relationship between CHL-RT and de novo CHL is not well understood.

    Immunogenomic characterization of classic Hodgkin lymphoma variant of Richter transformation reveals shared biology with de novo classic Hodgkin lymphoma · 2026 · DOI

  • The clinical and biological significance of clonal hematopoiesis (CH) has not been investigated in the myeloid compartment of chronic lymphocytic leukemia (CLL).

    Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation · 2026 · DOI

  • It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients treated with Bruton tyrosine kinase inhibitors.

    IGLV3‐21 R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL · 2026 · DOI

  • Finally, whereas low‐VAF variants affected outcomes in patients receiving chemoimmunotherapy, their impact on those treated with novel therapies remains undetermined.

    Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL · 2025 · DOI

  • One of the major limitations in studying the role of the microenvironment in tumor development and drug response is the inadequacy of conventional two-dimensional (2D) in vitro assays to physiologically reconstruct the complex spatial organization and interactions of cells in their natural lymphoid niches.

    A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia · 2025 · DOI

  • The synergistic ibrutinib-venetoclax combination remains understudied at low doses, particularly for ibrutinib.

    Optimizing Ibrutinib Posology in Chronic Lymphocytic Leukemia Using a Semi‐Mechanistic Pharmacometric Framework · 2025 · DOI

  • The cooccurrence of lower utilization of routine care services, along with higher utilization of acute care services among some individuals, has implications for patient burden and warrants further study.

    Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia · 2024 · DOI

  • One key limitation was that, because of data availability, pooled ibrutinib data and general population survival estimates were matched only for age and not for other individual patient characteristics.

    First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis · 2024 · DOI

  • While the prognostic value of measurable residual disease (MRD) in CLL has been extensively studied before, the role of BM assessments by IHC on trephine biopsies has not yet been evaluated.

    The role of trephine bone marrow biopsies in the era of measurable residual disease — Results from the CLL10 trial of the German CLL Study Group (GCLLSG) · 2024 · DOI

  • The study notes that the Medicare claims database lacks direct progression data, requiring the use of time to next treatment as a proxy for progression-free survival. The study also acknowledges the potential for intra-class switching of covalent Bruton's tyrosine kinase inhibitors, which may be due to tolerability issues rather than disease progression.

    Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline Setting · 2026 · DOI

  • The study only investigates the transmission of TSEs in sheep. The sample size is limited. The study does not investigate the transmission of TSEs in humans.

    Minimal residual disease in CLL: when does it really matter? · 2026 · DOI

  • There is a lack of understanding of the transmission of TSEs through blood transfusion. There is a need for studies on the risk of human-to-human transmission via blood transfusion or contaminated surgical instruments.

    Minimal residual disease in CLL: when does it really matter? · 2026 · DOI

  • These statistics are unknown in the South African setting due to both a lack of data and the likely underrecognition of this entity.

    A South African perspective on MYD88 and CXCR4 variants in lymphoplasmacytic lymphoma or Waldenström macroglobulinaemia · 2026 · DOI

  • The study identifies the challenge of statistical instability due to the limited event count. The study mentions the issue of wide confidence intervals and unexpected coefficient directions. The study notes the challenge of evaluating the risk of cancer recurrence due to the complexity and incompleteness of the dataset.

    An exploratory multimodal pipeline for recurrence prediction in CRC with XELOX therapy · 2026 · DOI

  • Limited knowledge of CNS adverse events, - Rarity and inaccessibility of lesions ante-mortem, - Lack of experts in this specific…

    Severe Brain Atrophy after Allogeneic Hematopoietic Stem Cell Transplantation in a Patient Suffering from Chronic Graft-versus-host Disease · 2026 · DOI

  • Clinical and basic research collaborations between hematologists, immunologists, and neurologists, - Studies on the anatomical and physiological correlates of psycho-neurological…

    Severe Brain Atrophy after Allogeneic Hematopoietic Stem Cell Transplantation in a Patient Suffering from Chronic Graft-versus-host Disease · 2026 · DOI

  • Further investigation into the prognostic significance of monotypic PCs bone marrow infiltration in WM, - Investigation into the effect of late clearance of PCs on response…

    Prognostic significance of monotypic plasma cell infiltration of the bone marrow in patients with Waldenström macroglobulinemia · 2026 · DOI

  • This was a retrospective study, - Flow cytometric analysis was limited to the markers in our clinically validated panel, - Bulk CLL/SLL sequencing inherently included rare HRS cells, which constitute less than 5% of total…

    Immunogenomic characterization of classic Hodgkin lymphoma variant of Richter transformation reveals shared biology with de novo classic Hodgkin lymphoma · 2026 · DOI

  • No standardized risk stratification guidelines, - Limited understanding of treatment resistance, - Small trials for BTK inhibitors and BCL2…

    Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies · 2026 · DOI

  • Investigation of BTK inhibitors and BCL2 inhibitors in cHCL, - Study of ROR1 and ROR2 targeting monoclonal antibodies, - Further research on disease velocity and its impact…

    Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies · 2026 · DOI

  • Only a few randomized trials and limited data are available for comparing different treatment approaches - The disease is rare, making it difficult to establish a single optimal treatment…

    Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions · 2026 · DOI

  • Further integration of molecular and microenvironmental data to enhance risk stratification - Development of more effective, tailored treatment…

    Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions · 2026 · DOI

  • No direct progression data in the Medicare claims database, - Limited to Medicare beneficiaries aged ≥65 years, - No results for <11 patients could be reported due to CMS cell suppression and patient privacy…

    Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline Setting · 2026 · DOI

Most-cited papers in Chronic Lymphocytic Leukemia Research

Most recent work

Find a gap in your own Chronic Lymphocytic Leukemia Research sub-topic

This page shows what the Chronic Lymphocytic Leukemia Research literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,200 open questions
Dementia and Cognitive Impairment Research
2,789 open questions
Substance Abuse Treatment and Outcomes
2,285 open questions
Cancer Immunotherapy and Biomarkers
2,273 open questions
Liver Disease Diagnosis and Treatment
2,102 open questions
Sports Performance and Training
1,952 open questions
Parkinson's Disease Mechanisms and Treatments
1,915 open questions
Mosquito-borne diseases and control
1,849 open questions
Open questions raised by papers listed on this page include: (1) The lack of understanding of the immune mechanisms underlying the onset of AIHA (“Autoimmune hemolytic anemia and chronic lymphocytic leukemia: crossing the…”, 2026); (2) The prognostic value of residual monotypic plasma cells after chemoimmunotherapy in patients with Waldenström macroglobulinemia remains unclear (“Prognostic significance of monotypic plasma cell infiltration of the bone…”, 2026); (3) The immune evasion phenotype of HRS cells in CHL-RT is not well understood (“Immunogenomic characterization of classic Hodgkin lymphoma variant of Richter…”, 2026); (4) The clinical and biological significance of clonal hematopoiesis (CH) has not been investigated in the myeloid compartment of chronic lymphocytic leukemia (CLL) (“Dissecting clonal hematopoiesis in the myeloid compartment of chronic…”, 2026); (5) It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients treated with Bruton tyrosine kinase inhibitors (“IGLV3‐21 R110 and ibrutinib treatment: Results from the double‐blind,…”, 2026). 315 gap statements have been mined from Chronic Lymphocytic Leukemia Research papers in our 7.9M-paper local library, which holds 1,599 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.